Concepedia

Yinghai Xie

YX

Statistics

Publications

11

Citations

310

H-Index

11

Active since

2019

Affiliations

Anhui University of Science and Technology(Current)

Guangzhou Medical University

Wuhu Institute of Technology

Guangzhou Blood Center

Jinan University

Yinghai Xie is an author at Anhui University of Science and Technology specializing in oncology, medicine, and pharmacology.

Publications per year

2019–2022

11

Publications

11

PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway.

Yinci Zhang, Chunmei Xie, Amin Li et al. · PubMed · 2019 · 44 citations

, , +17

LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells

Yongfang Ma, Ruyue Xu, Xueke Liu et al. · International Journal of Medical Sciences · 2021 · 38 citations · Full text

, , +17

LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway

Ruyue Xu, Yinci Zhang, Amin Li et al. · Molecular Medicine Reports · 2021 · 33 citations · Full text

, , +17

BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway.

Amin Li, Rongbo Zhang, Yinci Zhang et al. · PubMed · 2019 · 32 citations · Full text

, , +17

ASIC1a stimulates the resistance of human hepatocellular carcinoma by promoting EMT via the AKT/GSK3β/Snail pathway driven by TGFβ/Smad signals

Yinci Zhang, Niandie Cao, Jiafeng Gao et al. · Journal of Cellular and Molecular Medicine · 2022 · 31 citations · Full text

, , +17

1–5 of 11